Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01870024
Other study ID # P110123
Secondary ID 2012-003795-39
Status Completed
Phase Phase 3
First received
Last updated
Start date June 26, 2013
Est. completion date February 23, 2018

Study information

Verified date October 2018
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to know on one hand if lorazepam is more (effective) than clonazepam and on the other hand if lorazepam is also effective as the association clonazepam + fosphenytoin in out-of-hospital treatment of the generalized convulsive status epilepticus in adult patients.


Description:

Background: Early and rapid termination of status epilepticus with intravenous administration of benzodiazepines only or its association with other antiepileptic drug improves outcomes. Our out-of-hospital study aims to demonstrate on one hand the superiority of lorazepam compared with clonazepam and on the other hand the efficacy at least equivalent of lorazepam in comparison with the association clonazepam + fosphenytoin. If these hypotheses are demonstrated, the out-of-hospital treatment of the status epilepticus by lorazepam in monotherapy would then be strongly recommended, considering its efficacy and the simplicity of administration in the context of the pre-hospital emergency.Objective: To compare the efficacy of Lorazepam with that of Clonazepam and its association with Fosphenytoin for the treatment of out-of-hospital status epilepticus.

Participating centers: 41 prehospital emergency services employing mobile intensive care units and located in urban areas in France participated in this study. In France, the management of out-of-hospital medical emergencies is under the responsibility of the Service d'Aide Medicale Urgente (SAMU). Mobile intensive care units are staffed by an attending emergency physician or anesthesiologist, a nurse, and an ambulance driver. The study is coordinated by the prehospital emergency service of Lariboisiere Hospital, University Paris 7 (Paris, France)

Number of patients: 522 patients; 174 patients by group.

Duration of the study: The total duration planned is of 48 months Intermediate analysis: An intermediate analysis is planned while 261 patients will be included (50 % of the inclusions).Duration of participation of every patient: 24 hours Data collection: prehospital data recording during the 60 min period of the study, and intrahospital data recording by the medical report of hospitalization.

Methodology: Multicenter, randomized, double-blind trial with 3 arms.

Main criteria of evaluation: the cessation of the status epilepticus and the absence of recurrence from T20 minutes until T60 minutes after the beginning of the treatment.

The cessation of the status epilepticus is defined by the stop of any motor activity and any seizures or convulsive movements. The absence of recurrence is defined by the not occurrence of a new seizures after a period of cessation.


Recruitment information / eligibility

Status Completed
Enrollment 434
Est. completion date February 23, 2018
Est. primary completion date February 23, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients aged 18 years or older

- Out-of-hospital management

- presenting one of the criteria below noticed by the physician of the mobile intensive care unit:

1. convulsive seizures at the time of treatment and were reported by reliable witnesses to have been continuously convulsing for longer than 5 minutes, without regaining consciousness, or

2. if they were having more than 2 repeated convulsive seizures at the time of treatment without regaining consciousness

Exclusion Criteria:

- Patient having been already included in the study during a previous episode of status epilepticus

- Patient having already received before the arrival of the mobile intensive care unit one of theses studied drugs (lorazepam, clonazepam or fosphenytoin or phenytoin)

- Latent status epilepticus in deep coma

- Cerebral anoxia (post cardio respiratory arrest)

- Severe head trauma

- Patient presenting convulsive seizures of psychogenic origin

- Lennox Gastaut's syndrome

- Decision of urgent intubation

- Patients of more than 110 kg ( estimated weight

- Heart rate < 60 bpm or > 150 bpm

- Systolic Blood Pressure < 90 mmHg

- Atrioventricular block of 2nd or 3rd degree

- Ventricular tachycardia or ventricular fibrillation

- Sensibility known about benzodiazepines, fosphenytoin, phenytoin, other hydantoins, or barbiturate

- Contraindication known about benzodiazepines (severe respiratory failure, severe acute hepatic failure, myasthenia, syndrome of sleep apnea, glaucoma with closed angle

- Contraindication known about fosphenytoin (intermittent acute porphyry)

- Contraindication known about barbiturate (porphyry, severe respiratory failure, current treatment by saquinavir, ifosfamide and voriconazole, in association with millepertuis)

- Person unaffiliated in a National Social Security Insurance

- Pregnant or breast-feeding Woman

- Impossibility to put an intravenous or intra-osseous catheter for the treatment injection

- Absence of nurse in the mobile intensive care unit.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Clonazepam
clonazepam 0,015 mg/kg
Fosphenytoin
fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
Placebo
placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
Lorazepam
lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)

Locations

Country Name City State
France Département d'Anesthésie - Réanimation - SMUR - Hôpital Lariboisière Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patient with a cessation of seizures and absence of recurrence Percentage of patient with a cessation of seizures and absence of recurrence from 20 minutes until 60 minutes after the beginning of the treatment between 20 and 60 minutes after the beginning of the treatment
Secondary Duration between the first cessation and the recurrence of seizures Duration between the first cessation and the recurrence of seizures up to 60 minutes
Secondary Percentage of patients having had a second injection of benzodiazepine Percentage of patients having had a second injection of benzodiazepine up to 60 minutes
Secondary Percentage of patients having had an injection of the second line treatment Percentage of patients having had an injection of the second line treatment (i.e. Fosphenytoin or barbiturate) up to 60 minutes
Secondary Percentage of patients having a general anesthesia for refractory status epilepticus Percentage of patients having a general anesthesia for refractory status epilepticus up to 60 minutes
Secondary Percentage of patients having had a side effect Percentage of patients having had a side effect (low blood pressure, arrhythmias) up to 60 minutes
Secondary Percentage of patients having been mechanically ventilated Percentage of patients having been mechanically ventilated in pre-hospital setting up to 60 minutes
Secondary Glasgow Coma Scale Glasgow Coma Scale on arrival at the hospital 60 minutes
Secondary Mortality Mortality in pre-hospital setting up to 60 minutes
Secondary Mortality Mortality in hospital until J30 (if the patient still hospitalized) up to Day 30
Secondary Length of stay in Intensive Care Unit Length of stay in Intensive Care Unit up to Day 30
Secondary Length of stay in hospital Length of stay in hospital up to Day 30
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A